Table 2.
TILs distribution according to tumor subtype and clinical characteristics
| TILs %, median (Q1 – Q3): all patients 5 (2–10) | ||||||
|---|---|---|---|---|---|---|
| Overall | p value | TN | p value | HER2+ | p value | |
| Tumor phenotype | ||||||
| TN | 5 (2–10) | – | – | |||
| HER2+ | 5 (2–11) | 0.855 | – | – | – | – |
| Age at BC diagnosis | ||||||
| ≤ 50 years | 3 (2–8) | 0.002 | 3 (2–10) | 0.037 | 4 (2–8) | 0.010 |
| > 50 years | 8 (5–15) | 7 (4–11) | 9 (5–18) | |||
| HR status | ||||||
| Negative | – | – | – | – | 9 (5–15) | 0.029 |
| Positive | – | – | 4 (2–8) | |||
| Organ/site of biopsy | ||||||
| Liver | 5 (2–8) | 0.277 | 5 (5–11) | 0.936 | 5 (2–8) | 0.119 |
| Skin | 3(2–10) | 3 (2–10) | 4 (2–10) | |||
| Lung | 9 (5–18) | 8 (3–10) | 18 (6–19) | |||
| CNS | 6 (3–11) | 4 (3–38) | 11 (5–11) | |||
| Other | 5 (2–8) | 5 (2–19) | 5 (2–8) | |||
| Pre-biopsy systemic treatment for MBC | ||||||
| No | 5 (3–11) | 0.563 | 5 (3–10) | 0.104 | 4 (2–13) | 0.652 |
| Yes | 5 (2–8) | 2 (2–5) | 6 (5–9) | |||
Abbreviations: TILs tumor-infiltrating lymphocytes, Q1 first quartile, Q3 third quartile, p p value, significant values in bold, TN triple negative, HER2 human epidermal growth factor receptor-2, BC breast cancer, HR hormone receptor, CNS central nervous system, MBC metastatic breast cancer